Torrent Pharmaceuticals, an Ahmedabad-based company, has quickly established a dominant position in the generic semaglutide market, capturing 38% of the market share within just a month of its launch. Following the expiration of Novo Nordisk's patent in late March, over a dozen Indian companies introduced generic versions of semaglutide, generating approximately ₹44 crore in sales in April. Torrent's sales alone accounted for about ₹17 crore, significantly outpacing competitors like Zydus Lifesciences and Dr. Reddy's Laboratories, each with around ₹4 crore in sales. A key factor in Torrent's success is its dual offering of oral and injectable forms of semaglutide, which appeals to patients preferring tablets over injections. Experts note that the demand for oral semaglutide is so strong that pharmacies are experiencing shortages. The overall semaglutide market in India, including both generic and innovator products, saw total sales of around ₹88-90 crore in April, up from ₹59 crore in March. With the anti-obesity market expected to expand significantly, semaglutide could dominate the GLP1 market in the coming years.